Skip to content

Study · Case report or series · n = 1 · 2026

4 results

A case of type 2 diabetes with spinal and bulbar muscular atrophy treated with oral semaglutide while sparing muscle reduction for two years: a case report with literature review.

Nakano Y, Morita S, Nishi N, Kita M, Shimo N, Takeshima K, Furukawa Y, Matsuoka TA

Diabetology international9 Mar 2026

PMID41815887 (opens in a new tab)DOI10.1007/s13340-026-00882-w (opens in a new tab)PepBankPUB-41815887
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 65-year-old man with type 2 diabetes and SBMA on leuprorelin, glycemic parameters improved over two years of oral semaglutide.

    In plain wordsIn one man with diabetes and a muscle-wasting nerve disease, blood sugar measures improved over two years of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGlycemic parameters
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · two yearsAs given in this study (human).

    Source sentences

    Summary
    Over the following two years, improvements in glycemic parameters and reductions in fat mass were observed.
    2 context sentences
    Summary · context
    We report a case of a 65-year-old man with type 2 diabetes who developed progressive proximal muscle weakness and was subsequently diagnosed with spinal and bulbar muscular atrophy (SBMA), for which leuprorelin therapy was initiated.
    Summary · context
    At the age of 72, oral semaglutide was introduced.
  2. 02HumanCase report or seriesEfficacy outcome

    In this man, fat mass was reduced over two years of oral semaglutide.

    In plain wordsIn one man, body fat fell over two years of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat mass
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · two yearsAs given in this study (human).

    Source sentences

    Summary
    Over the following two years, improvements in glycemic parameters and reductions in fat mass were observed.
    2 context sentences
    Summary · context
    We report a case of a 65-year-old man with type 2 diabetes who developed progressive proximal muscle weakness and was subsequently diagnosed with spinal and bulbar muscular atrophy (SBMA), for which leuprorelin therapy was initiated.
    Summary · context
    At the age of 72, oral semaglutide was introduced.
  3. 03HumanCase report or seriesEfficacy outcome

    In this man, skeletal muscle mass was relatively preserved over two years of oral semaglutide, with only a minor annual decrease of 0.1 kg per year.

    In plain wordsIn one man, muscle mass was mostly kept over two years of oral semaglutide, with a small yearly loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseAnnual change in skeletal muscle mass
    Study

    n = 1

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · oral · two yearsAs given in this study (human).

    Measurements

    Annual decrease in muscle mass
    0.1 kg/year
    skeletal muscle mass

    Source sentences

    Summary
    Importantly, skeletal muscle mass and strength were relatively preserved, with only a minor annual decrease in muscle mass (- 0.1 kg/year), consistent with changes reported in previous studies of semaglutide-treated patients without neuromuscular conditions.
    2 context sentences
    Summary · context
    We report a case of a 65-year-old man with type 2 diabetes who developed progressive proximal muscle weakness and was subsequently diagnosed with spinal and bulbar muscular atrophy (SBMA), for which leuprorelin therapy was initiated.
    Summary · context
    At the age of 72, oral semaglutide was introduced.
  4. 04HumanCase report or seriesEfficacy outcome

    In this man, skeletal muscle strength was relatively preserved over two years of oral semaglutide.

    In plain wordsIn one man, muscle strength was mostly kept over two years of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeSkeletal muscle strength
    Study

    n = 1

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · oral · two yearsAs given in this study (human).

    Source sentences

    Summary
    Importantly, skeletal muscle mass and strength were relatively preserved, with only a minor annual decrease in muscle mass (- 0.1 kg/year), consistent with changes reported in previous studies of semaglutide-treated patients without neuromuscular conditions.
    2 context sentences
    Summary · context
    We report a case of a 65-year-old man with type 2 diabetes who developed progressive proximal muscle weakness and was subsequently diagnosed with spinal and bulbar muscular atrophy (SBMA), for which leuprorelin therapy was initiated.
    Summary · context
    At the age of 72, oral semaglutide was introduced.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.